Scynexis (SCYX) Preferred Stock Liabilities (2013 - 2014)

Scynexis (SCYX) reported Preferred Stock Liabilities of $4.2 million for Q1 2014, little changed quarter-over-quarter from $4.2 million in Q4 2013.

Scynexis (SCYX) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends

Scynexis has reported Preferred Stock Liabilities for 2 years, with the latest figure at $4.2 million in Q1 2014.

  • For the quarter ending Q1 2014, Preferred Stock Liabilities changed N/A year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2014 stood at $4.2 million (changed N/A YoY), and the FY2013 full-year result was $4.2 million, changed N/A from the prior year.
  • Preferred Stock Liabilities for Q1 2014 stood at $4.2 million, roughly flat from $4.2 million in the prior quarter.
  • The five-year high for Preferred Stock Liabilities was $4.2 million in Q4 2013, with the low at $4.2 million in Q4 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Teva Pharmaceutical Industries 39.97 Bn 36.23 Bn 1.97 Bn -
2 Zoetis 33.59 Bn 31.65 Bn 1.62 Bn -
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn -
4 Neurocrine Biosciences 16.10 Bn 14.78 Bn 800.70 Mn -
5 Aurora Cannabis 15.56 Bn 15.47 Bn 21.72 Mn -
6 Elanco Animal Health 12.04 Bn 11.61 Bn 785.00 Mn -
7 Alkermes 7.36 Bn 6.84 Bn -116.06 Mn -
8 Lantheus Holdings 6.74 Bn 6.24 Bn 230.92 Mn -
9 Liquidia 6.27 Bn 6.04 Bn 121.79 Mn -
10 Scynexis 221.66 Mn 162.40 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2014 4.22 Mn
Dec 31, 2013 4.22 Mn